Anthony Pak-Yin Liu

Dr. Anthony Pak-Yin Liu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
YNYoshiko Nakano
Yoshiko Nakano
IBIan Burns
Ian Burns
LNLiana Nobre
Liana Nobre
RSRobert Siddaway
Robert Siddaway
MRMansuba Rana
Mansuba Rana
ALAnthony Pak-Yin Liu
Anthony Pak-Yin Liu
Central nervous system germ cell tumors (CNS-GCT) are malignant neoplasms that arise predominantly during adolescence and young adulthood. These tumors are typically sensitive to treatment, but resulting long-term health deficits are common. Additional clinical challenges include surgical risks associated with tumor biopsy, and need to determine treatment response for adapting radiotherapy protocols. The aim of this study was to establish the detectability of circulating-tumor DNA (ctDNA) from cerebrospinal fluid (CSF) of children with CNS-GCT as a potential biomarker. We obtained CSF from patients with CNS-GCT by lumbar puncture or intra-operatively. Cell-free DNA (cfDNA) was extracted and subjected to low-pass whole genome sequencing (LP-WGS). Copy-number alterations (CNAs) were inferred and served as a marker of measurable residual disease (MRD). Comparisons with imaging findings and tumor marker levels were made. A total of 29 CSF samples from 21 patients (16 with germinoma, 5 with non-germinomatous GCT) were sequenced. Twenty samples from 19 patients were collected at diagnosis, and 9 samples from 7 patients were collected during or after therapy. Among the diagnostic samples, CNAs were detected in samples from 17/19 patients (89%), which included 8 with marker-negative tumors. Specific clinical scenarios suggested that serial cfDNA analysis may carry utility in tracking treatment responses as well as clarifying indeterminate imaging findings. Our results provide evidence for the high-sensitivity in detecting ctDNA from CSF of CNS-GCT patients using LP-WGS, with potential utility for non-invasive diagnosis and disease monitoring in upcoming CNS-GCT studies.

22 September 2025
Verified
Book Chapter
Closed access
ALAnthony Pak-Yin Liu
Anthony Pak-Yin Liu
HTHirokazu Takami
Hirokazu Takami
MAMohamed S Abdelbaki
Mohamed S Abdelbaki

4 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ELEvelyn Lu
Evelyn Lu
PCPui Wai Cheng
Pui Wai Cheng
SLSherman S. M. Lo
Sherman S. M. Lo
CSChloe W. Y. Siu
Chloe W. Y. Siu
CFChun ho Eric Fu
Chun ho Eric Fu
DSDeyond Y.W. Siu
Deyond Y.W. Siu
Background: Amino acid tracer positron emission tomography–magnetic resonance imaging (PET-MRI) was shown to be superior to MRI alone for evaluating central nervous system (CNS) tumours in adults. This study aimed to investigate the utility of amino acid PET-MRI in children with CNS tumours. Methods: We reviewed the amino acid PET-MRI findings of children with suspected or confirmed CNS neoplasms managed in a territory-wide referral centre in Hong Kong from 2022 to 2025. Maximal standardized uptake values (SUVmax) were captured, and tumour-to-background SUVmax ratios (TBRmax) were measured with reference to adjacent or contralateral normal brain structures. Comparisons were made among patients with clinical high-grade and low-grade/non-neoplastic lesions. Results: Thirty-seven patients were included, with 63 PET-MRIs performed. PET-MRI was performed as part of initial diagnostics in 41% of the cases, for response assessment in 48%, and evaluation of residual/relapsed disease in 11%. High-grade lesions had a significantly higher SUVmax and TBRmax compared to low-grade/non-malignant lesions (median SUVmax 3.7 vs. 1.6, p = 0.00006; median TBRmax 2.06 vs. 0.91, p = 0.00002). Optimal SUVmax and TBRmax cut-offs by ROC analysis were 2.38 and 1.62, respectively. Similar performance was reproduced by focusing on the subset of patients with suspected CNS germ cell tumours (CNS-GCT). The impact of amino acid PET availability is considerable, as clinical management was modified in 65% of patients. Conclusions: Our study demonstrates the performance and clinical utility of amino acid PET-MRI in the management of children with CNS pathologies. Amino acid PET-MRI contributes to the diagnosis, monitoring, and treatment guidance of these patients, providing crucial information for decision-making.

28 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CMChristy Yuen-Kwan Mak
Christy Yuen-Kwan Mak
DKDennis TL Ku
Dennis TL Ku
ALAnthony Pak-Yin Liu
Anthony Pak-Yin Liu
VLVincemt Lee
Vincemt Lee
JYJeffrey PW Yau
Jeffrey PW Yau
ECEugene YH Chan
Eugene YH Chan
Background: The long-term kidney outcomes in paediatric osteosarcoma survivors treated with nephrotoxic chemotherapeutic agents are not well-described. Methods: We conducted a multi-centre retrospective cohort study and recruited paediatric osteosarcoma survivors who survived beyond 5 years from cancer diagnosis over a 20-year period. Chronic kidney disease (CKD) was defined as evidence of kidney impairment, chronic tubulopathy, and proteinuria upon last follow-up. Results: We included 89 patients (57% males) with a mean follow-up period of 14.9 years. A total of 42 subjects (47.2%) developed CKD, 28 of whom had CKD stage 1 with either chronic tubulopathy or proteinuria; 14 patients had CKD stage 2 (eGFR < 90 mL/min/1.73 m2), while two had CKD stage 3 (eGFR < 60 mL/min/1.73 m2). Chronic tubular dysfunction was reported in 34 patients (38%), with hypomagnesemia being the most common manifestation. Proteinuria and hypertension were infrequently observed, in 3% and 8% of cases, respectively. We found that a history of severe AKI and aminoglycoside exposure during the treatment course were significant risk factors for CKD, but the dose-dependent relationships between the development of CKD and cisplatin, ifosfamide, and methotrexate could not be demonstrated. Conclusions: CKD is prevalent among paediatric osteosarcoma survivors. Caution is needed when using multiple nephrotoxic agents at the same time, as this could increase the risk of CKD in the long run. Multi-disciplinary regular surveillance should be performed to identify and manage CKD early, including kidney function, electrolyte, and proteinuria monitoring.

11 April 2026 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
YWYuliang Wang
Yuliang Wang
WCWing Lam Chan
Wing Lam Chan
FLFei Li
Fei Li
JCJiaoyang Cai
Jiaoyang Cai
YCYin Ting Cheung
Yin Ting Cheung
WTWinnie Wan-Yee Tso
Winnie Wan-Yee Tso
Purpose: Survival rates for children with brain tumors improve, highlighting the importance of understanding the long-term neurobehavioral outcomes because of its impact on children’s well-being and quality of life. This study investigated the prevalence of attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and emotional/behavioral difficulties in pediatric brain tumor survivors (PBTS), and identified the risks and protective factors on mental well-being. Methods: A territory-wide retrospective cohort included 274 PBTS registered in the Hong Kong Paediatric Haematology and Oncology Study Group Registry. In addition, a cross-sectional follow-up survey on mental well-being was completed by 107 PBTS during survivorship follow-up. Emotional/behavioral difficulties, health-related quality of life, parental stress, and sleep variables were assessed by the survey and benchmarked against previously published Hong Kong-based reference/community cohorts. Results: Among 274 PBTS, 10.6% had ADHD and 6.9% had ASD, which are significantly higher than the general pediatric population prevalence. They had more emotional/behavioral symptoms, higher parental stress, and poorer quality of life. Younger age at diagnosis, seizure history, and supratentorial tumors were linked to more difficulties. Radiotherapy was associated with reduced quality of life. Better sleep correlated with fewer ADHD and emotional symptoms. Conclusion: PBTS had increased risk of ADHD and ASD, and are more vulnerable to peer-relationship difficulties, poorer mental health, and quality of life. Improving sleep could be key to reducing neurobehavioral challenges. Implementing routine neurobehavioral monitoring, including sleep assessments, is crucial for enhancing survivorship care and overall well-being.

23 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ELEvelyn Lu
Evelyn Lu
CHCalvin P. L. Hoo
Calvin P. L. Hoo
HCHo Ming Cheung
Ho Ming Cheung
IWI. W. C. Wong
I. W. C. Wong
KFKin Fen Kevin Fung
Kin Fen Kevin Fung
GCGodfrey C. F. Chan
Godfrey C. F. Chan
Background: The integration of anti-disialoganglioside GD2 (anti-GD2) immunotherapy during induction chemotherapy has emerged as a promising strategy to improve outcomes in high-risk neuroblastoma (HR-NB). This study evaluated the end-of-induction (EOI) response and tolerability of a modified N7 induction regimen combined with dinutuximab beta in a Hong Kong paediatric cohort. Methods: A retrospective territory-wide analysis was conducted on nine HR-NB patients treated from 2022 to 2025. They received a modified N7 chemotherapy backbone with dinutuximab beta (17.5 mg/m2/day for 4 days per cycle), alongside granulocyte–macrophage colony-stimulating factor (GM-CSF) and low-dose interleukin-2. Response was assessed using the Revised International Neuroblastoma Response Criteria (INRC), and toxicity was graded according to the Common Terminology Criteria for adverse events (CTCAE). Results: The EOI objective response rate was 78% (7/9 patients) for the primary tumour site and 100% at metastatic sites. No patient exhibited progressive disease. A modified Curie score of ≤2 on MIBG scan was achieved in 78% of patients. Grade 3 or higher toxicities, including neutropenic fever, enterocolitis, and capillary leak syndrome, were observed in eight patients but were manageable. Conclusions: The incorporation of dinutuximab beta into a modified N7 induction regimen demonstrates a satisfactory EOI response rate and a manageable safety profile in children with HR-NB. These preliminary results support the feasibility of this chemoimmunotherapy approach and warrant further investigation in larger cohorts to confirm its efficacy in long-term survival outcomes.